Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. See the press release.
Read moreResearch has answered some questions about UBE3A’s role in seizures ASF-funded research conducted at Dr. Ben Philpot’s lab at the University of North Carolina-Chapel Hill has answered some questions about UBE3A’s role in seizures in individuals with Angelman syndrome, and […]
Read more
The ASF Celebrates the Opening of the New Angelman Syndrome Clinic at Mayo Clinic One-Stop Facility Provides Comprehensive Support for Individuals with Angelman syndrome from Infancy through Adulthood ROCHESTER, Minn., November 30, 2015 – Mayo Clinic and the Angelman Syndrome Foundation […]
Read more
Angelman Syndrome Foundation-Funded Research at University of North Carolina-Chapel Hill Leads to Breakthrough in AS- and Autism-related research Research from the lab of Dr. Mark Zylka, a leading AS researcher and associate professor of cell biology and physiology at the […]
Read more
Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome . . .
Read more
ASF-Funded Research Discovers Possible Therapeutic for Angelman Syndrome Promising ASF-funded research continues to move closer toward possible clinical trials, as announced today in a paper in Nature by Dr. Art Beaudet and his research team at Baylor College of Medicine. The ASF […]
Read morePNAS Paper shows ASF-funded Research at UNC Making Progress The ASF continues to lead the charge in funding research that is making progress towards treatments and ultimately a cure for Angelman syndrome, having invested more than $8 million during the […]
Read more
ASF invests $1.5 million to support 17 Angelman Syndrome Clinics across the U.S. Furthering its direct support of individuals with Angelman syndrome and their families, the Angelman Syndrome Foundation has committed $1.5 million to establish 17 comprehensive Angelman Syndrome Clinics across the […]
Read more